Physician profile
Mohammed Khan
NPI 1144218025
$2,900.16
in general payments reported to CMS, 2019-2025
27 companies · $508 in 2025
The $508 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $451 · 2020: $227 · 2021: $69.34 · 2022: $292 · 2023: $1,281 · 2024: $70.96 · 2025: $508.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,140 · Travel and Lodging: $720.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,140.15 |
| Travel and Lodging | $719.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Research & Development, LLC | $1,009.78 | 2023 | |
| Janssen Pharmaceuticals, INC | $245.23 | 2019-2023 | Xarelto |
| United Therapeutics Corporation | $223.65 | 2019-2025 | Tyvaso, Tyvaso |
| Boston Scientific Corporation | $208.10 | 2022-2025 | Cds - Mct/Cem Monitoring, Watchman Access System, Watchman Flx |
| Novartis Pharmaceuticals Corporation | $192.57 | 2019-2023 | |
| Amgen INC. | $128.08 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $100.25 | 2022 | |
| Medtronic Vascular, INC. | $91.62 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $82.50 | 2019 | |
| Surmodics, INC. | $76.94 | 2025 | Pounce Thrombectomy System, Sublime 014 Rx Pta Balloon Dilatation Catheter, Pounce Thrombectomy |
| Medtronic, INC. | $69.34 | 2021 | |
| Amarin Pharma, INC. | $52.44 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $47.08 | 2020-2025 | Camzyos |
| Stryker Corporation | $47.08 | 2023 | Pro-Dense |
| Cvrx, INC. | $46.19 | 2023-2024 | Barostim Neo System |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $42.35 | 2019 | |
| Pfizer INC. | $39.53 | 2019-2025 | |
| Actelion Pharmaceuticals US, INC. | $38.39 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.45 | 2024 | Jardiance |
| Kestra Medical Technology Services, INC. | $29.65 | 2025 | Assure Wcd |
| Bayer Healthcare Pharmaceuticals INC. | $22.06 | 2022 | |
| Alnylam Pharmaceuticals INC. | $20.98 | 2022 | |
| Abiomed | $20.44 | 2025 | |
| Merck Sharp & Dohme LLC | $19.36 | 2022 | |
| Vital Connect, INC | $14.10 | 2025 | Vitalpatch Rtm |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.